Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases
Status:
Terminated
Trial end date:
2018-03-31
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to see whether addition of TPI 287 to FSRT is safe and
tolerable. Researchers also want to find out if adding TPI 287 to FSRT can help with better
controlling the growth of brain lesions in people with brain metastases from their cancer.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute